uniQure is an innovative gene therapy company focused on rare genetic diseases. uniQure’s lead product on the market is Glybera, a drug to treat a potentially life-threatening, rare metabolic disease. Glybera is the first gene therapy ever to receive regulatory approval in the EU.

Definiens is the leading provider of image analysis for digital pathology. Definiens’ revolutionary approach provides unprecedented accuracy which helps physicians select the best cancer treatment for every cancer patient.

Fysius is a chain of clinics for patients suffering from lower-back and related pains. With over 35,000 treated patients annually, Fysius is the largest specialized clinic for back pain in the Netherlands. Gilde supported Fysius with the further expansion of locations and the optimization of its quality of care.

Inova Labs markets portable oxygen concentrators for patients suffering from respiratory conditions such as COPD or asthma. Portable oxygen concentrators like the LifeChoice® Activox can give patients their freedom back to engage in regular daily activities. Gilde actively supports the international marketing and sales activities of Inova Labs.

Stepping Stones operates intimate, high-quality private nursing homes with 24/7 specialized healthcare and residential services to elderly patients suffering from Alzheimer’s disease.The Gilde investment enables Stepping Stones to become the first national chain of private nursing homes specialized in dementia in the Netherlands.